Cargando…
Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial
INTRODUCTION. GeneXpert® MTB/RIF (Xpert) is now widely distributed in high human immunodeficiency virus (HIV)/tuberculosis (TB)-burden countries. Yet, whether the test improves patient-important outcomes within HIV treatment programs in limited resource settings is unknown. METHODS. To investigate...
Autores principales: | Mupfumi, L., Makamure, B., Chirehwa, M., Sagonda, T., Zinyowera, S., Mason, P., Metcalfe, J. Z., Mutetwa, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324195/ https://www.ncbi.nlm.nih.gov/pubmed/25734106 http://dx.doi.org/10.1093/ofid/ofu038 |
Ejemplares similares
-
Cost-effectiveness of Xpert(®)MTB/RIF in the diagnosis of tuberculosis: pragmatic study
por: da Silva, Suely Conceição Alves, et al.
Publicado: (2021) -
Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis
por: Hanrahan, Colleen F., et al.
Publicado: (2016) -
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults
por: Horne, David J, et al.
Publicado: (2019) -
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults
por: Kohli, Mikashmi, et al.
Publicado: (2021) -
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children
por: Kay, Alexander W, et al.
Publicado: (2020)